JP2023522907A5 - - Google Patents
Info
- Publication number
- JP2023522907A5 JP2023522907A5 JP2022563379A JP2022563379A JP2023522907A5 JP 2023522907 A5 JP2023522907 A5 JP 2023522907A5 JP 2022563379 A JP2022563379 A JP 2022563379A JP 2022563379 A JP2022563379 A JP 2022563379A JP 2023522907 A5 JP2023522907 A5 JP 2023522907A5
- Authority
- JP
- Japan
- Prior art keywords
- ccl24
- optionally
- pharmaceutical composition
- monoclonal antibody
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013793P | 2020-04-22 | 2020-04-22 | |
| US63/013,793 | 2020-04-22 | ||
| PCT/IL2021/050447 WO2021214759A1 (en) | 2020-04-22 | 2021-04-20 | Method of treatment using anti-ccl24 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522907A JP2023522907A (ja) | 2023-06-01 |
| JP2023522907A5 true JP2023522907A5 (cg-RX-API-DMAC7.html) | 2024-04-11 |
Family
ID=75787181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563379A Pending JP2023522907A (ja) | 2020-04-22 | 2021-04-20 | 抗ｃｃｌ２４抗体を使用する処置方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230235037A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4139352A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023522907A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230013037A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115427445A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021259682A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3172627A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296579A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021214759A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121022A (en) * | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| JP4762156B2 (ja) * | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション，インコーポレイテッド | Ｆｃ領域変異体 |
| AU2010209273A1 (en) | 2009-01-28 | 2011-09-01 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders |
| CA2777013A1 (en) * | 2009-10-16 | 2011-04-21 | Mochida Pharmaceutical Co., Ltd. | Marker associated with non-alcoholic steatohepatitis |
| SG184355A1 (en) * | 2010-03-01 | 2012-11-29 | Progenics Pharm Inc | Concentrated protein formulations and uses thereof |
| US10246508B2 (en) | 2014-03-04 | 2019-04-02 | Chemomab Ltd. | Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines |
| CA2957722C (en) * | 2014-08-19 | 2022-05-31 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| EP3191126B1 (en) * | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| US20180008707A1 (en) * | 2015-02-13 | 2018-01-11 | Sanofi | Stable liquid formulation for monoclonal antibodies |
| EP3433274A1 (en) * | 2016-03-25 | 2019-01-30 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
| IL326479A (en) * | 2016-10-12 | 2026-04-01 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
| IL251024A0 (en) * | 2017-03-08 | 2017-06-29 | Chemomab Ltd | Antibodies against eutaxin 2 for use in the treatment of liver diseases |
| CN107198773A (zh) * | 2017-06-08 | 2017-09-26 | 上海药明生物技术有限公司 | 重组抗pd‑l1全人单克隆抗体的液体制剂 |
| CA3071234A1 (en) * | 2017-07-27 | 2019-01-31 | Daiichi Sankyo Company, Limited | Anti-cd147 antibody |
| CN109745559A (zh) * | 2017-11-01 | 2019-05-14 | 三生国健药业（上海）股份有限公司 | 抗人il-17a的单克隆抗体的液体制剂 |
| CN110354073B (zh) * | 2018-04-09 | 2021-10-01 | 鲁南制药集团股份有限公司 | 一种免疫抑制剂单克隆抗体的液体制剂 |
-
2021
- 2021-04-20 KR KR1020227040238A patent/KR20230013037A/ko active Pending
- 2021-04-20 US US17/996,386 patent/US20230235037A1/en active Pending
- 2021-04-20 AU AU2021259682A patent/AU2021259682A1/en active Pending
- 2021-04-20 CA CA3172627A patent/CA3172627A1/en active Pending
- 2021-04-20 CN CN202180029962.8A patent/CN115427445A/zh active Pending
- 2021-04-20 JP JP2022563379A patent/JP2023522907A/ja active Pending
- 2021-04-20 WO PCT/IL2021/050447 patent/WO2021214759A1/en not_active Ceased
- 2021-04-20 IL IL296579A patent/IL296579A/en unknown
- 2021-04-20 EP EP21723427.7A patent/EP4139352A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7446356B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| AU2018227036B2 (en) | Formulations of monoclonal antibodies | |
| CN101495146B (zh) | 肌肉再生促进剂 | |
| JP4890537B2 (ja) | 安定化抗ｂ型肝炎ウイルス（ｈｂｖ）抗体製剤 | |
| KR101320198B1 (ko) | 신생물의 치료를 위한 조성물 및 방법 | |
| JP2020509031A5 (cg-RX-API-DMAC7.html) | ||
| CN112741804A (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| JP2024508762A5 (cg-RX-API-DMAC7.html) | ||
| RS66930B1 (sr) | Elafibranor za upotrebu u lečenju primarnog bilijarnog holangitisa | |
| TW200932262A (en) | Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient | |
| PE20050586A1 (es) | Preparacion farmaceutica que comprende un anticuerpo contra el receptor egfr | |
| CN112203695A (zh) | 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法 | |
| JP2024001125A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| JP2024540377A5 (cg-RX-API-DMAC7.html) | ||
| JP2024540395A5 (cg-RX-API-DMAC7.html) | ||
| TW202426050A (zh) | 穩定抗體組合物 | |
| JP2023507981A5 (cg-RX-API-DMAC7.html) | ||
| JP7355326B2 (ja) | 経粘膜投与薬剤 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| TW202144007A (zh) | 一種抗ｐｄ－１抗體在製備治療肢端黑色素瘤的藥物中的用途 | |
| JP2021533149A5 (cg-RX-API-DMAC7.html) | ||
| JP7754490B2 (ja) | アジュバント組成物 | |
| WO2025056005A1 (zh) | 抗tim-3抗体的药物组合物及用途 | |
| Ford Jr et al. | Immunologic Competence of Alveolar Cells: II. Modification of the Plaque-Forming Response by Inhibitors, Tolerance, and Chronic Stimulation |